EichorEICHOR
Condition: Ret Fusion Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · August 02, 2026

Recruiting studies: Ret Fusion Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06147570Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Phase 4 · 2 location(s) · Rigel Pharmaceuticals · NCT07704658Patient-centered, Optimal Integration of Survivorship and Palliative Care
NA · 1 location(s) · Massachusetts General Hospital · NCT04900935Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: RO
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01639508
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.